Literature DB >> 3295641

Multifocal static creamy choroidal infiltrates. An early sign of lymphoid neoplasia.

F A Jakobiec, E Sacks, J W Kronish, T Weiss, M Smith.   

Abstract

Three patients, each more than 60 years of age at initial presentation, had early stage lymphoid infiltrates (formerly called reactive lymphoid hyperplasia) of the choroid and contiguous extraocular tissues. There were multifocal, confluent, and nonconfluent creamy patches in the choroid. These lesions changed very little over periods of observation ranging from 1 to 4 years and failed to produce ophthalmoscopically visible disturbances of the retinal pigment epithelium (RPE). Fluorescein angiography demonstrated dye collection within the lesions without leakage into the subretinal or subpigment epithelial spaces. Both ultrasonography and computed tomography (CT) showed thickening of the choroid with either anterior or posterior episcleral extensions of lymphoid tissue. Pathologic evaluation of biopsy specimens of extraocular portions of the lesions showed low-grade tumors that were diffuse infiltrates of mature lymphocytes, which exhibited lymphoplasmacytoid features, Dutcher bodies, or small residual germinal centers (so-called borderline lesions). Two patients had uniocular localized disease, whereas the third had bilateral ocular lesions, hypogammaglobulinemia, and another extranodal chest wall lymphoid tumor. Therapy for the localized ocular condition consisted either of oral administration of corticosteroids or low doses of radiotherapy.

Entities:  

Mesh:

Year:  1987        PMID: 3295641     DOI: 10.1016/s0161-6420(87)33453-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  13 in total

1.  Diagnosis of a primary uveal extranodal marginal zone B-cell lymphoma by chorioretinal biopsy: case report.

Authors:  Sarah E Coupland; Antonia Joussen; Gerasimos Anastassiou; Harald Stein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-07       Impact factor: 3.117

2.  The possible role of herpes viruses in multifocal choroiditis and panuveitis.

Authors:  E Frau; E Dussaix; H Offret; E Bloch-Michel
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

3.  An overview of ocular adnexal lymphoid tumors.

Authors:  F A Jakobiec; D M Knowles
Journal:  Trans Am Ophthalmol Soc       Date:  1989

4.  Gadolinium enhanced magnetic resonance imaging in the diagnosis of anterior visual pathway meningiomas.

Authors:  M G Alper; J L Sherman
Journal:  Trans Am Ophthalmol Soc       Date:  1989

5.  Intraocular non-Hodgkin's lymphoma treated with systemic and intrathecal chemotherapy and radiotherapy. A case report and review of the literature.

Authors:  A J Rouwen; P W Wijermans; T N Boen-Tan; J S Stilma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

6.  [Diagnostics and treatment of primary vitreoretinal lymphoma].

Authors:  N Stübiger; V Kakkassery; E Gundlach; S Winterhalter; U Pleyer
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

7.  [Diagnostics and treatment of choroidal lymphoma].

Authors:  D Doycheva; M Zierhut; D Süsskind; K U Bartz-Schmidt; C Deuter
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

Review 8.  Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features.

Authors:  Sarah E Coupland; Heinrich Heimann; Nikolaos E Bechrakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-10-29       Impact factor: 3.117

9.  Primary intraocular inflammatory myofibroblastic tumor with anaplastic lymphoma kinase overexpression.

Authors:  Alfredo E Romero-Rojas; Julio A Diaz-Perez; Melina Mastrodimos; Jose Szelezsan; Oscar Messa-Botero
Journal:  Int Ophthalmol       Date:  2013-09-13       Impact factor: 2.031

10.  Uveal lymphoid infiltrates: immunohistochemical evidence for a lymphoid neoplasia.

Authors:  D Ben-Ezra; J A Sahel; N L Harris; I Hemo; D M Albert
Journal:  Br J Ophthalmol       Date:  1989-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.